In this tumour, the malignant component is of fibroblastic origin and express RANKL, which provokes osteoclastogenesis (Murata et al, 2005).
Vimentin was identified in the cytoplasm of non-luminal cells of ductal formations, in plasmacytoid and spindle cells of PA and canine MT, in all MC cells, and was identified diffusely in Ca ex-PA with myoepithelial differentiation (those which the malignant component was described as myoepithelial, adenoid cystic, and polymorphous low-grade adenocarcinomas).
Immunohistochemistry showed that the malignant epithelial components were positive for CK-7 and TTF-1, but negative for CK20 and thyroglobulin.
Thus, given the atypia and the Ki-67 PI of the original and xenograft tumors, it is suggested that more malignant components may be selected by repeated xenotransplantation.
RISC mRNA and miRNA components were profiled by microarray analysis of malignant human U-87 astrocytoma cells and its non-malignant counterpart, primary human astrocytes.
The components were interchangeable.
36 components were extracted.
In contrast to loss of TGF-β receptors in tumour tissue we found frequent activation of Smad signalling indicated by nuclear expression of Smad3 and Smad4 in tumour and surrounding stroma, but only nuclear expression of Smad4 in the malignant epithelial component was correlated to presence of lymph node metastasis.
However, despite evidence in nonmalignant cells (Eierman et al, 1989), the induction of cytokine secretion in malignant cells by ECM components is yet to be investigated.
The percentage of cells comprising invasive malignant disease and non-malignant components (that is, in situ disease, inflammatory infiltrate, non-malignant ductal/lobular structures, and fibroblastic involvement) were recorded by consensus between two breast pathologists.
